Chiropractic News | Chiropractic Magazine
Your Online Chiropractic Community
Chiropractic Social Network - Facebook Chiropractic Social Network - Twitter Chiropractic Social Network - Linkedin Chiropractic Social Network - Pinterest Chiropractic Social Network - Google Plus Chiropractic Social Network - YouTube Chiropractic Social Network - RSS
 
 
Featured Resources:

Resource Centers:(News, information, and tools to support your practice)


Chiropractic News

May 2008

Article Tools
Comment on this story

Share on your Social Network Post to Facebook Post to LinkedIn Post to Twitter

Chiropractic News from Reuters

Cancer drug sales could hit $80 bln by 2011IMS

NEW YORK (Reuters) - Sales of cancer drugs will grow at nearly double the rate of the global pharmaceutical market and could reach $80 billion by 2012, according to IMS Health, which tracks prescription drug sales.

Expensive new treatments, an increasing number of patients on chemotherapy in major markets and evidence that more people in emerging markets are gaining access to modern targeted therapies will contribute to sales of cancer drugs growing at a compound rate of 12 to 15 percent, IMS said.

In 2008, sales of oncology products will exceed $48 billion, contributing nearly 17 percent of global pharmaceutical sales growth this year, according to the IMS Global Oncology Forecast released on Thursday.

"Double-digit sales growth in oncology drugs will be fueled by increased use of targeted therapeutic agents introduced over the past 10 years, along with first-time innovations coming to the market and longer treatment periods for growing numbers of

patients," Titus Plattel, IMS vice president for oncology, said in a statement.

IMS expects growth to be fueled by the introduction of 25 to 30 new chemical entities between 2008 and 2012, as expensive new biotechnology drugs and the increasing use of combination therapies contribute to the exploding cost of treatment.

Data from clinical studies of many of the newest cancer drugs will be presented and discussed at the nation's largest oncology meeting later this month in Chicago. Much of the data will be unveiled on Thursday ahead of the American Society of Clinical Oncology meeting.

Several factors could serve to moderate growth over the next five years, IMS said. They include financial constraints of payers, slowing growth of some current blockbuster therapies and patent expirations of four cancer drugs with annual sales exceeding $1 billion, including Eli Lilly's Gemzar and Taxotere from Sanofi-Aventis.

(Reporting by Bill Berkrot; editing by Carol Bishopric)

Share on your social network

Comments


Be the first to comment on this Article

Name
 
Location
 
Comment
Limited to 500 Characters. You have characters left.
To submit your comment, please type the security word shown in the picture. imgCaptcha
Remember information
 
 

 

Chiropractic Economics Magazine - A Chiropractic Publication

Chiropractic News



Campaign for Chiropractic

Chiropractic Economics ©2014 | 5150 Palm Valley Rd. Suite 103 | Ponte Vedra Beach, FL 32082 | P:904.285.6020 F:904.285.9944